- ￥985.60
- LC labs
- 美国
- LC2-Q-4747
- 2025年07月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
见说明书
- 保质期：
＞1年
- 英文名：
Quizartinib Free Base
- 库存：
期货2-3周
- 供应商：
上海经科化学科技有限公司
- CAS号：
950769-58-1
- 规格：
1mg
供应商：上海经科化学科技有限公司
服务热线：400-0199-638
QQ:472482400(上海经科）
微信号：shjkchem
活动：消费积分可换充值卡！
本试剂(Quizartinib (AC220))
仅供科研实验使用,不得用于其他用途！
货 号：LC2-Q-4747
名 称：Quizartinib (AC220)
别 名：Quizartinib Free Base
C A S ：950769-58-1
分子量：560.67
分子式：C29H32N6O4S
纯 度：HPLC/TLC:>99%
说 明：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
文 献：Quizartinib has high affinity for FLT3 in a binding assay (Kd = 1.6 nM) and is a potent inhibitor in cellular autophosphorylation assays (IC50 = 1.1 nM for FLT3-ITD and 4.2 nM for wt FLT3). It inhibits the growth of human leukemia cell line MV4-11 (IC50 = 0.56 nM) which is FLT3 dependent and contains a homozygous FLT3-ITD mutation, and A375 cells (IC50 > 10,000 nM) which are not FLT3 dependent and contain an activating mutation in BRAF. Quizartinib inhibits FLT3 activity in subcutaneous MV4-11 tumor xenografts. Treatment with quizartinib at 10 mg/kg in MV4-11 tumor xenografts results in rapid and complete regression of tumors. Quizartinib prolongs the survival of mice injected with MV4-11 cells in a dose-dependent manner. Zarrinkar, P.P., et al. "AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)." Blood 114: 2984-2992 (2009). Quizartinib inhibited the autophosphorylation of wt FLT3 and FLT3/ITD with IC50 values of 5 and 1 nM, respectively. However, the cytotoxic effect of quizartinib was not exclusively dependent on inhibition of FLT3 autophosphorylation. It depended on the clinical status of acute myoloid leukemia and FLT3-mutant allelic burden. Relapsed samples and samples with a high mutant allelic burden were more sensitive to the cytotoxic effect from FLT3 inhibition by quizartinib compared with the samples obtained at diagnosis or those with a low mutant allelic burden. Pratz, K.W., et al. "FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML." Blood 115: 1425-1432 (2010). Quizartinib has demonstrated significant promise in early phases of clinical investigation with patients with acute myeloid leukemia (AML), and is now in more advanced clinical trials. Fathi, A.T. and Chabner, B.A. "FLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations." The Oncologist 16: 1162-1174 (2011). Quizartinib has demonstrated significant promise in early phases of clinical investigation with patients with acute myeloid leukemia (AML), and is now in more advanced clinical trials. Fathi, A.T. and Chabner, B.A. "FLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations." The Oncologist 16: 1162-1174 (2011).
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Isolation of Sequences Flanking Ac Insertion Sites by Ac Casting
Localizing Ac insertions is a fundamental task in studying Ac -induced mutation and chromosomal rearrangements involving Ac elements. Researchers may sometimes be faced with the situation in which the sequence flanking one side of an Ac /Ds
AC-Electrokinetic Applications in a Biological Setting
Dielectrophoresis is a phenomenon which can be exploited to provide significant quantitative electrophysiological data in a range of biochemical setting, from oncology to drug discovery. This chapter seeks to elucidate those applications
Transposon Tagging with AC/Ds in Arabidopsis
(2 ‐5 ). In Arabidopsis, Actzvator/Dissoclation (AC/ Ds) have been used to isolate recessive loss-of-function mutations (6 —8 ), dommant gain of function mutations (9 ) and to isolate genes based on then patterns of expression (10 ,11 ).
技术资料暂无技术资料 索取技术资料
